Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine whether treatment with Armodafinil
(CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness
associated with narcolepsy by measuring mean sleep latency from the Maintenance of
Wakefulness Test (MWT) (20-minute version)(average of 4 naps at 0900, 1100, 1300, and 1500)
and by the Clinical Global Impressions of Change (CGI-C) ratings (as related to general
condition) at week 12 (or last postbaseline observation)